Cvrx, Inc. (CVRX) — SEC Filings
Cvrx, Inc. (CVRX) — 34 SEC filings. Latest: 8-K (Apr 13, 2026). Includes 19 8-K, 6 10-Q, 3 SC 13G/A.
Overview
Cvrx, Inc. (CVRX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 6, 2025: CVRx, Inc. reported revenue of $14.69 million for the three months ended September 30, 2025, an increase of 9.8% from $13.37 million in the same period of 2024. For the nine months ended September 30, 2025, revenue grew to $40.63 million, up 13.0% from $35.95 million in the prior year. Despite reven
Sentiment Summary
Across 34 filings, the sentiment breakdown is: 1 bearish, 29 neutral, 4 mixed. The dominant filing sentiment for Cvrx, Inc. is neutral.
Filing Type Overview
Cvrx, Inc. (CVRX) has filed 19 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 2 SC 13D/A, 3 SC 13G/A with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (34)
Risk Profile
Risk Assessment: Of CVRX's 26 recent filings, 2 were flagged as high-risk, 6 as medium-risk, and 18 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $40.63M |
| Net Income | ($41.37M) |
| EPS | $ (1.59) |
| Cash Position | $85.12M |
| Total Assets | $111.325M |
| Total Debt | $49.453M |
Key Executives
- Dr. Robert L. Carels
- Dr. David M. Steinhaus
- ANTHONY A. FLORENCE, JR.
- MOHAMAD H. MAKHZOUMI
- SCOTT D. SANDELL
- Dr. Robert L. Smith
- Dr. David E. Pearlstone
- Mudit Jain
- Kirk Nielsen
- Martha Shadan
Industry Context
CVRx operates in the highly competitive medical device sector, specifically focusing on implantable neuromodulation for cardiovascular conditions. The industry is characterized by significant R&D investment, long product development cycles, and stringent regulatory approvals. Key trends include the increasing demand for innovative treatments for chronic diseases like heart failure and the ongoing consolidation among larger players.
Top Tags
financial-reporting (5) · corporate-governance (5) · financials (5) · 10-Q (4) · 8-K (4) · Medical Devices (3) · sec-filing (3) · executive-compensation (3) · financial-condition (3) · CVRx (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Q3 2025 Revenue | $14.69M | Increased 9.8% from $13.37M in Q3 2024 |
| Nine Months 2025 Revenue | $40.63M | Increased 13.0% from $35.95M in prior year |
| Q3 2025 Net Loss | ($12.87M) | Slight improvement from ($13.10M) in Q3 2024 |
| Nine Months 2025 Net Loss | ($41.37M) | Improvement from ($49.31M) in prior year |
| Cash and Cash Equivalents | $85.12M | Decreased from $105.93M at Dec 31, 2024 |
| Net Cash Used in Operating Activities | ($30.41M) | For the nine months ended September 30, 2025 |
| Accumulated Deficit | $578.72M | As of September 30, 2025, indicating significant historical losses |
| Shares Outstanding | 26,193,733 | As of September 30, 2025 |
| Net Loss (Q2 2025) | $25.97M | Increased from $21.43M in Q2 2024, indicating worsening profitability. |
| Net Loss (YTD 2025) | $26.07M | Higher than $21.63M for the same period in 2024, reflecting sustained losses. |
| Common Stock Shares Outstanding (Q2 2025) | 0.57 | Represents the number of common stock shares outstanding. |
| Common Stock Shares Outstanding (Q1 2025) | 0.65 | Represents the number of common stock shares outstanding. |
| Total Assets | $258.76M | As of March 31, 2025 |
| Total Liabilities | $21.23M | As of March 31, 2025 |
| Fiscal Year End | 2024-12-31 | Reporting period for the 10-K |
Forward-Looking Statements
- {"claim":"CVRx, Inc. will continue to operate within the Surgical & Medical Instruments & Apparatus sector.","entity":"CVRx, Inc.","targetDate":"2025-12-31","confidence":"high"}
Frequently Asked Questions
What are the latest SEC filings for Cvrx, Inc. (CVRX)?
Cvrx, Inc. has 34 recent SEC filings from Jan 2024 to Apr 2026, including 19 8-K, 6 10-Q, 3 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of CVRX filings?
Across 34 filings, the sentiment breakdown is: 1 bearish, 29 neutral, 4 mixed. The dominant sentiment is neutral.
Where can I find Cvrx, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Cvrx, Inc. (CVRX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Cvrx, Inc.?
Key financial highlights from Cvrx, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for CVRX?
The investment thesis for CVRX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Cvrx, Inc.?
Key executives identified across Cvrx, Inc.'s filings include Dr. Robert L. Carels, Dr. David M. Steinhaus, ANTHONY A. FLORENCE, JR., MOHAMAD H. MAKHZOUMI, SCOTT D. SANDELL and 5 others.
What are the main risk factors for Cvrx, Inc. stock?
Of CVRX's 26 assessed filings, 2 were flagged high-risk, 6 medium-risk, and 18 low-risk.
What are recent predictions and forward guidance from Cvrx, Inc.?
Recent forward-looking statements from Cvrx, Inc. include guidance on {"claim":"CVRx, Inc. will continue to operate within the Surgical & Medical Instruments & Apparatus sector.","entity":"C.